Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Tongue Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Non-Muscle Invasive Bladder Neoplasms 1Lymphoid Interstitial Pneumonia 1Keratosis, Actinic 1Esophageal Squamous Cell Carcinoma 1Epitheliod Malignant Pleural Mesothelioma 1Carcinoma, Transitional Cell 1Carcinoma, Basal Cell 1

Interventions

Gemcitabine 12Mitomycin 6Docetaxel 4Radiotherapy 3BCG Vaccine 3tislelizumab 2erdafitinib 2dodecyl maltoside 2disitamab vedotin 2toripalimab 1pemigatinib 1pembrolizumab 1monalizumab 1linrodostat 1enzalutamide 1durvalumab 1bicalutamide 1avelumab 1Watchful Waiting 1Sugars 1Postoperative Period 1Pentosan Sulfuric Polyester 1Nonsteroidal Anti-Androgens 1Nivolumab 1Metformin 1Imiquimod 1Hyaluronic Acid 1High-Intensity Interval Training 1Gels 1Epirubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Non-Muscle Invasive Bladder Neoplasms × 1-phenyl-3,3-dimethyltriazene × Clear all
NCT03945162 2025-11-24

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

TheralaseĀ® Technologies Inc.

Phase 2 Recruiting
90 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚔